Dr. John Cush RheumNow
6 years 9 months ago
301 fibromyalgia #FM pts randomized to receive active‐TENS or placebo‐TENS or no‐TENS to use at home 2h/day for 4 wks. Active TENS had greater reduction in pain & fatigue vs placeboAND better global improvement (70% vs. 31%, p<0.0001) https://t.co/AH84DxlTo3
Dr. John Cush RheumNow
6 years 9 months ago
CORRONA registry 880 RA pts developed a solid cancer. 42% taking bDMARD/tsDMARD; 5% switched biologics w/in 36 mos & 10% started a new biologic- w/ most changing to a TNFi (53%). ACR guidelines say to Rx regardless of solid tumor https://t.co/pPgnYNdT7Q
Dr. John Cush RheumNow
6 years 9 months ago
high-dose trivalent inactivated influenza vaccine (HD-TIV) was studied in 696 RA patients compared to standard-dose quadrivalent flu vaccine - Seroconversion was 3 fold higher w/ HD-TIV, no differences in side effects and no increase in RA flares https://t.co/1JBs95vGSA
Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.
Dr. John Cush RheumNow
6 years 9 months ago
Claims data from RA patients (n = 12,182), shows that screening for hyperlipidemia was suboptimal (compared to Diabetes pts), Those seeing a PCP and Rheum were 36% more likely to be screened. https://t.co/j661loTDGk
Dr. John Cush RheumNow
6 years 9 months ago
From the 9/11 World Trade Center registry, 118 persons found w/ a CTD (RA=71, Sjӧgrens 22, SLE 20, myositis 9,MCTD 7, PSS 4. Responders w/ intense dust cloud exposure had 2 fold CTD risk & Community members w/ PTSD had 3‐fold risk. https://t.co/07GhloezNA
Dr. John Cush RheumNow
6 years 9 months ago
2019 YEAR IN REVIEW Podcast is up! Superheros, women, New Drugs, Novel Approaches, Failed drugs, MTX, Who's killing medicine & low dose pred Watch here>> https://t.co/sYb3KvivJK or Podcast Listen on iTunes https://t.co/FlPe6BQ3BW or Soundcloud >> https://t.co/FlPe6BQ3BW
Dr. John Cush RheumNow
6 years 9 months ago
2019 YEAR IN REVIEW Podcast is up! Superheros, women, New Drugs, Novel Approaches, Failed drugs, MTX, Who's killing medicine & low dose pred Watch here>> https://t.co/sYb3KvivJK or Podcast Listen on iTunes https://t.co/FlPe6BQ3BW or Soundcloud >> https://t.co/FlPe6BQ3BW
Dr. John Cush RheumNow
6 years 9 months ago
Check out my 2019 Rheumatology Year in Review - now on RheumNow https://t.co/sYb3KvivJK
Dr. Jack Cush reviews highlights from 2019 on RheumNow.com. Topics covered in this annual review include: superheroes lost; venous thromboembolic events and JAKs; free medical tuition; women in rheumatology; 52 new drug approvals in 2019 and 330 drugs with a 2020 price hike; scleroderma disappointments; novel new treatments and newer tests; the boom of Shingrix; RheumNow.Live - and more.
Dr. John Cush RheumNow
6 years 9 months ago
Rates of "indeterminate" results on quantiferon-IT assays were found to be significantly higher in systemic vasculitis (21%) than nonvasculitis pts and controls (7-7.5%). Indeterminate predictors were Syst vasculitis (OR 9.64), high NLR (OR 1.70). https://t.co/roZINmKgZ1
Dr. John Cush RheumNow
6 years 9 months ago
Internet based study by Choi et al - looked at 517 gout patients and examined if gout flares were associated with vaccination. They found a twofold higher odds of gout flare (adjusted OR 1.99; 95% CI 1.01 to 3.89 in those who were vaccinated (any vaccine). https://t.co/dSkG6d1ay5
Dr. John Cush RheumNow
6 years 9 months ago
anti-MDA5+ amyopathic dermatomyositis (ADM) with ILD is severe and refractory. NEJM letter reports on 18 ADM Rx w/ tofacitinibs who showed better 6 mo survival (100% vs 78%) (P=0.04) and improved ferritin, FVC, DLCO, & CT Chest over time. https://t.co/H8JPkVrQqR
Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.
